Positive botulinum toxin type a response is a prognosticator for migraine surgery success

Plastic and Reconstructive Surgery

Volumn 131, Issue 4, 2013, Pages 751-757

  Lee, Michelle ^a   Monson, Mikhal A ^a   Liu, Mengyuan T ^a   Reed, Deborah ^a   Guyuron, Bahman ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; MUSCLE RELAXANT AGENT;

ADULT; ARTICLE; FOLLOW UP; HUMAN; MIGRAINE; PROGNOSIS; REMISSION;

ADULT; BOTULINUM TOXINS, TYPE A; FOLLOW-UP STUDIES; HUMANS; MIGRAINE DISORDERS; NEUROMUSCULAR AGENTS; PROGNOSIS; REMISSION INDUCTION;

MLCS; MLOWN;

EID: 84878061323     PISSN: 00321052     EISSN: None     Source Type: Journal    
DOI: 10.1097/PRS.0b013e3182818b7f     Document Type: Article

References (28)

1. Menken M, Munsat TL, Toole JF. The global burden of disease study: Implications for neurology. Arch Neurol. 2000; 57:418-420.
2. Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007;68:343-349.
3. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: Data from the American Migraine Study II. Headache 2001; 41:646-657.
4. Patel NV, Bigal ME, Kolodner KB, Leotta C, Lafata JE, Lipton RB. Prevalence and impact of migraine and probable migraine in a health plan. Neurology 2004;63:1432-1438.
5. World Health Organization. World Health Report 2002: Reducing Risks, Promoting Healthy Life. Geneva: World Health Organization; 2002.
6. World Health Organization. The Global Burden of Disease. Geneva: World Health Organization; 2004.
7. Sprenger T, Goadsby PJ. Migraine pathogenesis and state of pharmacological treatment options. BMC Med. 2009;7:71.
8. Binder WJ, Brin MF, Blitzer A, Schoenrock LD, Pagoda JM. Botulinum toxin type A (Botox) for treatment of migraine headaches: An open-label study. Otolaryngol Head Neck Surg. 2000;123:669-676.
9. Diener HC, Dodick DW, Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010;30:804-814.
10. Aurora SK, Dodick DW, Turkel CC, et al. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010;30:793-803.
11. Brin MF. Botulinum toxin: Chemistry, pharmacology, toxicity, and immunology. Muscle Nerve Suppl. 1997;6:S146-S168.
12. Guyuron B, Kriegler JS, Davis J, Amini SB. Comprehensive surgical treatment of migraine headaches. Plast Reconstr Surg. 2005;115:1-9.
13. Liu MT, Armijo BS, Guyuron B. A comparison of outcome of surgical treatment of migraine headaches using a constellation of symptoms versus botulinum toxin type A to identify the trigger sites. Plast Reconstr Surg. 2012;129:413-419.
14. Guyuron B, Reed D, Kriegler JS, Davis J, Pashmini N, Amini S. A placebo-controlled surgical trial of the treatment of migraine headaches. Plast Reconstr Surg. 2009;124:461-468.
15. Guyuron B, Becker DB. Surgical management of migraine headaches. In: Guyuron B, Eriksson E, Persing JA, et al, eds. Plastic Surgery: Indications and Practice. New York: Elsevier; 2009; 1655-1665.
16. Dirnberger F, Becker K. Surgical treatment of migraine headaches by corrugator muscle resection. Plast Reconstr Surg. 2004;114:652-657; discussion 658-659.
17. Poggi JT, Grizzell BE, Helmer SD. Confirmation of surgical decompression to relieve migraine headaches. Plast Reconstr Surg. 2008;122:115-122; discussion 123-124.
18. Janis JE, Ghavami A, Lemmon JA, Leedy JE, Guyuron B. Anatomy of the corrugator supercilii muscle: Part I. Corrugator topography. Plast Reconstr Surg. 2007;120:1647-1653.
19. Janis JE, Ghavami A, Lemmon JA, Leedy JE, Guyuron B. The anatomy of the corrugator supercilii muscle: Part II. Supraorbital nerve branching patterns. Plast Reconstr Surg. 2008; 121:233-240.
20. Mosser SW, Guyuron B, Janis JE, Rohrich RJ. The anatomy of the greater occipital nerve: Implications for the etiology of migraine headaches. Plast Reconstr Surg. 2004;113:693-697; discussion 698-700.
21. Janis JE, Hatef DA, Ducic I, et al. The anatomy of the greater occipital nerve: Part II. Compression point topography. Plast Reconstr Surg. 2010;126:1563-1572.
22. Janis JE, Hatef DA, Thakar H, et al. The zygomaticotemporal branch of the trigeminal nerve: Part II. Anatomical variations. Plast Reconstr Surg. 2010;126:435-442.
23. Totonchi A, Pashmini N, Guyuron B. The zygomaticotemporal branch of the trigeminal nerve: An anatomical study. Plast Reconstr Surg. 2005;115:273-277.
24. Behin F, Behin B, Bigal ME, Lipton RB. Surgical treatment of patients with refractory migraine headaches and intranasal contact points. Cephalalgia 2005;25:439-443.
25. Janis JE, Dhanik A, Howard JH. Validation of the peripheral trigger point theory of migraine headaches: Single-surgeon experience using botulinum toxin and surgical decompression. Plast Reconstr Surg. 2012;128:123-131.
26. Guyuron B, Kriegler JS, Davis J, Amini SB. Five-year outcome of surgical treatment of migraine headaches. Plast Reconstr Surg. 2010;127:603-608.
27. Larson K, Lee M, Davis J, Guyuron B. Factors contributing to migraine headache surgery failure and success. Plast Reconstr Surg. 2011;128:1069-1075.
28. Chepla KJ, Oh E, Guyuron B. Clinical outcomes following supraorbital foraminotomy for treatment of frontal migraine headache. Plast Reconstr Surg. 2012;129:656e-662e.